KDR and neoplasm: Another tyrosine kinase inhibitor (Vatalanib) was shown to inhibit VEGF-mediated angiogenesis, thus reducing tumor growth and metastasis by blocking VEGFR-1, VEGFR-2, and VEGFR-3 [24].